Hanmi Receives First Korea FDA Approval For Generic Of BMS’ Baraclude
This article was originally published in PharmAsia News
Hanmi is the first to clear regulatory hurdles to sell the country’s best-selling hepatitis B therapy after patent expiration in 2015, though the distinction doesn’t carry the same benefits as it once did.
You may also be interested in...
TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.